Brief: Tracon Pharmaceuticals Announces Positive Results Based On Ongoing Double-Digit Objective Response Rate For Single Agent Envafolimab In The Envasarc Phase 2 Pivotal Trial
20/06/2023 15:23
June 20 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS BASED ON
ONGOING DOUBLE-DIGIT OBJECTIVE RESPONSE RATE FOR SINGLE AGENT
ENVAFOLIMAB IN THE ENVASARC PHASE 2 PIVOTAL TRIAL
* TRACON PHARMACEUTICALS INC - SINGLE AGENT ENVAFOLIMAB ORR
EXCEEDED FUTILITY RULE THAT WILL BE APPLIED AT INTERIM EFFICACY
ANALYSIS EXPECTED IN Q3
* TRACON PHARMACEUTICALS INC - FULL ENVASARC ACCRUAL
EXPECTED IN
Q4
Source text for Eikon: ID:nGNX190gBj
Further company coverage: TCON.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants